Introduction to Refractory B

Immunotherapy with T cells engineered to express a chimeric antigen receptor (CAR T cells) is reshaping the management of patients with relapsed or refractory B-cell malignancies.

Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma.

In Europe, tisagenlecleucel (Kymriah™) has a marketing authorization for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and young adults and for the relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

This therapy is now standard of care for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), the most common malignancy of childhood, and in high-grade B-cell lymphomas, the most common lymphoma in Canada.

In this study, the first observations of the size distribution and mixing state of individual refractory black carbon (rBC) particles in the South Asian outflow to the south-eastern Arabian Sea and the northern and equatorial Indian Ocean regions are presented based on measurements using a single particle soot photometer (SP2) aboard the Integrated Campaign for Aerosols, gases, and Radiation Budget (ICARB-2018) ship during winter 2018 (16 January to 13 February).

Number concentrations of refractory black carbon (rBC) measured by a single particle soot photometer ranged from 200 to 1200 cm−3 when SAPs were observed.

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with relapsed/refractory B-cell malignancies, however, is associated with toxicities including cytokine release syndrome (CRS), neurotoxicity, and impaired hematopoietic recovery.

CD19-targeted chimeric antigen receptor (CAR) T cell therapy has shown high efficacy in patients with refractory B-cell malignancies such as non-Hodgkin lymphoma and acute lymphoblastic leukemia.

OBJECTIVE Tisagenlecleucel is a CD19-directed, genetically modified, autologous T-cell immunotherapy indicated for pediatric and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia and for adult patients with relapsed/refractory diffuse large B-cell lymphoma.

The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

CD19-targeting chimeric antigen receptor (CAR) T cells have become an important therapeutic option for patients with relapsed and refractory B cell malignancies.

To the Editor: CD19-targeting chimeric antigen receptor T (CAR-T) cell therapy is a revolutionary immunotherapy in treating relapsed or refractory B lineage malignancies.

BACKGROUND Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for more effective therapies.

Blinatumomab is a BiTE® (bispecific T‐cell engager) immuno‐oncology therapy, which has demonstrated significant activity in patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia (R/R B‐ALL); however, a subset of patients relapse.

Furthermore, the encouraging activity of novel therapies such as inotuzumab and blinatumomab in chemo-refractory B-cell ALL has promoted an interest in introducing these agents early in Ph-like ALL management, which may lead to improved cure rates with frontline therapies, sparing more adults from undergoing early allogeneic hematopoietic cell transplantation (HCT).

Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative for relapsed or refractory B-cell lymphomas (BCL), though outcomes are worse in aggressive disease and most patients will still experience relapse.

Background: Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men and usually becomes refractory because of recurrence and metastasis.

Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men and usually becomes refractory because of recurrence and metastasis.

Are presents findings on the influence of the direction of transmission and the natural frequency of transducers on ultrasonic pulse method measurements of silica refractory bricks.

Are presents findings on the influence of the direction of transmission and the natural frequency of transducers on ultrasonic pulse method measurements of silica refractory bricks.

Levofloxacin, Enrofloxacin, Ofloxacin cause refractory basophilia.

Rarely, it may arise in the small intestine and cause refractory bleeding [1].

Fireclay refractory bricks were used for furnishing as they directly interfaced with the molten metal, while the flame blower was connected, assembled, and erected in the different segments.

Fireclay refractory bricks were used for furnishing as they directly interfaced with the molten metal, while the flame blower was connected, assembled, and erected in the different segments.

OBJECTIVE Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies.

Background The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL).

To the Editor: CD19-targeting chimeric antigen receptor T (CAR-T) cell therapy is a revolutionary immunotherapy in treating relapsed or refractory B lineage malignancies.

Chimeric antigen receptor (CAR) T cells directed against CD19 have achieved impressive outcomes for the treatment of relapsed/refractory B lineage lymphoid neoplasms.